Related Experiment Video
Updated: Jun 18, 2025

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
Published on: March 1, 2022
Increased Secreted Frizzled-Related Protein 2 in Hypertension-Induced Left Ventricular Remodeling
Mengying Cao1,2, Xueli Jiang1,2, Xiaolin Wang1,2
1Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 200032 Shanghai, China.
Insights
Secreted frizzled-related protein 2 (sFRP2) is elevated in hypertension patients with left ventricular remodeling. This biomarker shows potential for distinguishing cardiac remodeling in hypertensive individuals.
Area of Science:
- Cardiovascular Biology
- Biomarker Discovery
- Hypertension Research
Background:
- Secreted frizzled-related protein 2 (sFRP2) plays a role in cardiovascular diseases.
- The specific role of sFRP2 in left ventricular (LV) remodeling among hypertension (HTN) patients remains unclear.
Purpose of the Study:
- To investigate the association between serum sFRP2 levels and LV remodeling in patients with HTN.
- To evaluate sFRP2 as a potential diagnostic marker for LV remodeling in HTN.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) to measure serum sFRP2 levels in 196 HTN patients and 100 controls.
- Echocardiography to assess LV remodeling; Receiver Operating Characteristic (ROC) curve analysis to determine diagnostic value.
- Spearman correlation and Western blot/qPCR to analyze sFRP2 expression and correlations.
Main Results:
- Serum sFRP2 levels were significantly higher in HTN patients with LV remodeling compared to those without.
- ROC analysis indicated sFRP2 has a notable distinguishing value (AUC = 0.791) for LV remodeling in HTN.
- sFRP2 expression was elevated in hypertrophic hearts and correlated with LV dimensions and relative wall thickness (RWT).
Conclusions:
- Serum and cardiac sFRP2 levels are elevated in the context of LV remodeling in HTN patients.
- sFRP2 demonstrates potential as a valuable biomarker for identifying LV remodeling in hypertensive individuals.
- Myricetin treatment showed a potential to reverse increased sFRP2 expression.
Background:
Secreted frizzled-related protein 2 (sFRP2) is involved in various cardiovascular diseases. However, its relevance in left ventricular (LV) remodeling in patients with hypertension (HTN) is obscure.
Methods:
In this study, 196 patients with HTN were included, 59 with echocardiographic LV remodeling. A total of 100 healthy subjects served as normal controls. The serum-sFRP2 level was measured by enzyme-linked immunosorbent assay (ELISA). Data were collected from medical records for baseline characteristics, biochemistry tests, and echocardiography. Receiver operating characteristic (ROC) curves were used to assess the distinguishing value of sFRP2 for LV remodeling in patients with HTN. Spearman rank correlation analysis was utilized to identify factors correlated with sFRP2. Cardiac sFRP2 was determined by Western blot and quantitative polymerase chain reaction (qPCR).
Results:
The level of serum-sFRP2 was higher in HTN patients with echocardiographic LV remodeling than their non-remodeling counterparts. ROC analysis showed that the area under the curve (AUC) for sFRP2 in distinguishing echocardiographic LV remodeling in HTN patients was 0.791 (95% confidence interval (CI): 0.714-0.869). The sFRP2 was negatively correlated with LV dimension and positively correlated with relative wall thickness (RWT). The expression of sFRP2 was higher in hypertrophic hearts, which could be reversed by myricetin.
Conclusions:
The serum level and cardiac sFRP2 increased in the setting of LV remodeling and decreased by myricetin. Serum sFRP2 may be a promising distinguishing factor for LV remodeling in HTN patients.
More Related Videos
07:13A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
09:23Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Hormonal Regulation of Blood Pressure
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Heart Failure Drugs: Diuretics
Pathophysiology of Heart Failure